Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

MLA

Maria Vieito Villar, et al. “Abstract CT033: Inducible T Cell Costimulatory (ICOS) Receptor Agonist, Feladilimab (FE), Alone and in Combination (Combo) with Pembrolizumab (PE): Results from INDUCE-1 Relapsed/Refractory (R/R) Melanoma Expansion Cohorts (EC).” Cancer Research, vol. 81, July 2021, p. CT033. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........3d9b7c93a073d91a373e87c6b7de4a05&authtype=sso&custid=ns315887.

APA

Maria Vieito Villar, Courtney Henry, Sapna Yadavilli, Victor Moreno, Antoine Italiano, Omid Hamid, Marc S. Ballas, Marco Balas, Michael Chisamore, Frans L. Opdam, Michele Maio, Xiao Ji, Jeffrey S. Weber, Axel Hoos, David C. Turner, Jose Manuel Trigo, & Catherine E. Ellis. (2021). Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC). Cancer Research, 81, CT033.

Chicago

Maria Vieito Villar, Courtney Henry, Sapna Yadavilli, Victor Moreno, Antoine Italiano, Omid Hamid, Marc S. Ballas, et al. 2021. “Abstract CT033: Inducible T Cell Costimulatory (ICOS) Receptor Agonist, Feladilimab (FE), Alone and in Combination (Combo) with Pembrolizumab (PE): Results from INDUCE-1 Relapsed/Refractory (R/R) Melanoma Expansion Cohorts (EC).” Cancer Research 81 (July): CT033. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........3d9b7c93a073d91a373e87c6b7de4a05&authtype=sso&custid=ns315887.